Zobrazeno 1 - 10
of 30
pro vyhledávání: '"George Apostol"'
Autor:
Randi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, Vincent Des Portes, Andrew Stanfield, Barbara Koumaras, Gerd Rosenkranz, Alessandra Murgia, Christian Wolf, George Apostol, Florian von Raison
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
Abstract Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral e
Externí odkaz:
https://doaj.org/article/b0c86247e00a4aa7a01f18f018f9be46
Autor:
Jean-Charles Bizot, Fabienne Massé, Julie Combeau, Norinne Lacerda-Queiroz, Sabrina David, Laurent Benel, George Apostol, Eric Konofal
Publikováno v:
SLEEP. 46:A11-A11
Introduction The chronic fatigue syndrome (CFS) is a heterogeneous disorder characterized by easy fatigability, feverishness, diffuse pains, and depression. Many COVID-19 patients expressed a long-term effect of coronavirus (long-COVID), with some ch
Autor:
Thomas Stern, Bruce Corser, Richard Bogan, Jennifer Franco, Eric Konofal, George Apostol, Russell Rosenberg, Anne Morse, Michael Thorpy, Clete Kushida
Publikováno v:
SLEEP. 46:A261-A261
Introduction Mazindol ER (extended-release), the first partial orexin-2 receptor agonist and triple mono-aminergic reuptake inhibitor, has demonstrated efficacy and safety in significantly reducing excessive daytime sleepiness (EDS) and cataplexy att
Autor:
Richard Bogan, Thomas Stern, Bruce Corser, Jennifer Franco, Eric Konofal, George Apostol, Anne Morse, Russell Rosenberg, Michael Thorpy, Clete Kushida
Publikováno v:
SLEEP. 46:A260-A260
Introduction Efficacy secondary outcome measure Functional Outcomes of Sleep Questionnaire, Short Version (FOSQ-10] was collected in the Phase 2 (POLARIS, NLS-1021), multicenter (n=21) study of mazindol ER in adult participants with narcolepsy type 1
Autor:
Richard Bogan, Thomas Stern, Bruce Corser, Jennifer Franco, Eric Konofal, George Apostol, Anne Morse, Clete Kushida, Michael Thorpy, Russell Rosenberg
Publikováno v:
SLEEP. 46:A254-A254
Introduction Mazindol is the first partial orexin 2 receptor agonist and triple monoamine reuptake inhibitor in development for the treatment of narcolepsy. Clinician and Patient Global Impression (CGI and PGI, respectively) for cataplexy and excessi
Autor:
Bruce Corser, Thomas Stern, Richard Bogan, Jennifer Franco, George Apostol, Eric Konofal, Anne Morse, Russell Rosenberg, Clete Kushida, Michael Thorpy
Publikováno v:
SLEEP. 46:A257-A257
Introduction Mazindol is the first partial orexin 2 receptor agonist and triple monoamine reuptake inhibitor in development for the treatment of narcolepsy. A novel extended release (ER) formulation was developed to allow once-daily dosing and may pr
Autor:
Raj Vuppalanchi, Alejandro Dorenbaum, David Jones, Gideon M. Hirschfield, George Apostol, Joan Gu, Bruce R. Bacon, Ciara Kennedy, Marlyn J. Mayo, Cynthia Levy, Velimir A. Luketic, Sharon Medendorp, I Patanwala, Patricia Novak, Christopher L. Bowlus, Paul J. Pockros
Publikováno v:
Hepatology communications, vol 3, iss 3
Hepatology Communications
Hepatology Communications
Primary biliary cholangitis (PBC) is typically associated with elevated serum bile acid levels and pruritus, but pruritus is often refractory to treatment with existing therapies. This phase 2 study assessed the efficacy and safety of maralixibat, a
Autor:
Gerd K. Rosenkranz, George Apostol, Alessandra Murgia, Christian Wolf, Vincent des Portes, Randi J Hagerman, Elizabeth Berry-Kravis, Barbara Koumaras, Andrew C. Stanfield, Sébastien Jacquemont, Florian Von Raison
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
Scientific Reports
Scientific reports, vol 8, iss 1
Hagerman, R, Jacquemont, S, Berry-Kravis, E, Des Portes, V, Stanfield, A, Koumaras, B, Rosenkranz, G, Murgia, A, Wolf, C, Apostol, G & von Raison, F 2018, ' Mavoglurant in Fragile X Syndrome : Results of two open-label, extension trials in adults and adolescents ', Scientific Reports, vol. 8, no. 1, pp. 16970 . https://doi.org/10.1038/s41598-018-34978-4
Scientific reports, vol. 8, no. 1, pp. 16970
Scientific Reports
Scientific reports, vol 8, iss 1
Hagerman, R, Jacquemont, S, Berry-Kravis, E, Des Portes, V, Stanfield, A, Koumaras, B, Rosenkranz, G, Murgia, A, Wolf, C, Apostol, G & von Raison, F 2018, ' Mavoglurant in Fragile X Syndrome : Results of two open-label, extension trials in adults and adolescents ', Scientific Reports, vol. 8, no. 1, pp. 16970 . https://doi.org/10.1038/s41598-018-34978-4
Scientific reports, vol. 8, no. 1, pp. 16970
Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in
Publikováno v:
Water, Vol 16, Iss 18, p 2559 (2024)
Continuous measurements of soil moisture in the deeper parts of the unsaturated zone remain an important challenge. This study examines the development of an integrated system for the continuous and 3-D monitoring of the vadose zone processes in a co
Externí odkaz:
https://doaj.org/article/4f8fc835d4ba4fabb2b8f09480087abd
Autor:
Florian Von Raison, Randall L. Carpenter, Will Spooren, George Apostol, Jacqueline N. Crawley, Eva Loth, Elizabeth Berry-Kravis, Lothar Lindemann, Vincent des Portes, Farah Hossain, Mark F. Bear, Randi J Hagerman, Sebastian H. Scharf, Baltazar Gomez-Mancilla, Paul P. Wang, David R Hessl, Sébastien Jacquemont, Fabrizio Gasparini, Aia E. Jønch, Aurore Curie
Publikováno v:
Other repository
Berry-Kravis, E M, Lindemann, L, Jønch, A E, Apostol, G, Bear, M F, Carpenter, R L, Crawley, J N, Curie, A, Des Portes, V, Hossain, F, Gasparini, F, Gomez-Mancilla, B, Hessl, D, Loth, E, Scharf, S H, Wang, P P, Von Raison, F, Hagerman, R, Spooren, W & Jacquemont, S 2018, ' Drug development for neurodevelopmental disorders : lessons learned from fragile X syndrome ', Nature Reviews. Drug Discovery, vol. 17, no. 4, pp. 280–299 . https://doi.org/10.1038/nrd.2017.221
Nature reviews. Drug discovery, vol 17, iss 4
Berry-Kravis, E M, Lindemann, L, Jønch, A E, Apostol, G, Bear, M F, Carpenter, R L, Crawley, J N, Curie, A, Des Portes, V, Hossain, F, Gasparini, F, Gomez-Mancilla, B, Hessl, D, Loth, E, Scharf, S H, Wang, P P, Von Raison, F, Hagerman, R, Spooren, W & Jacquemont, S 2018, ' Drug development for neurodevelopmental disorders : lessons learned from fragile X syndrome ', Nature Reviews. Drug Discovery, vol. 17, no. 4, pp. 280–299 . https://doi.org/10.1038/nrd.2017.221
Nature reviews. Drug discovery, vol 17, iss 4
Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of intellectual disability and autism, and the und